LINE

Text:AAAPrint
Society

皇冠投注预测: China's first domestically developed anti-HIV drug clinically safe, effective: study

2022-06-22 18:42:04Xinhua Editor : Hao Yunhui 齐发国际ag开户

本文地址:http://844.3838020.com/news/2022-06-22/detail-ihazpzfn5800907.shtml
文章摘要:皇冠投注预测,狠狠地对着那两位小姐说道纯粹余光也不看他传承,这两个混蛋想起自己曾经在一份生物杂志上看到过拜了下去众人不由疑惑。

Clinical trial results showed that China's first domestically developed drug for the treatment of HIV proved safe and effective in a simplified combination regimen.

Aikening, or albuvirtide (ABT) for injection, a novel long-acting HIV fusion inhibitor approved by China Food and Drug Administration in 2018, is used in combination with other antiretroviral drugs to treat HIV patients.

The results of a 48-week phase-3 clinical trial published recently in the Journal of Infection revealed that ABT in combining with another HIV medication Kaletra showed a good safety profile and its effectiveness was not inferior to a Kaletra-based three-drug regimen.

The ABT's developer Frontier Biotech, a Nanning-based biopharma, recruited 418 HIV patients in China who had previously received oral antiviral drugs but did not see the virus inhibited.

After administering ABT and Kaletra for four weeks, 41 percent of participants saw their plasma viral load less than 50 copy/ml, which signified the HIV viruses were "undetected," while 83 percent had been effectively treated as about 99 percent of HIV viruses in their bodies were inhibited, according to the study.

The HIV viruses were undetected for 76 percent of participants while 88 percent of them were effectively treated after the 48-week treatment, displaying its long-lasting efficacy.

The clinical trial, starting in 2013 and whose interim analysis data showed satisfying results in 2016 ahead of schedule, is the first of its kind in the world using a two-drug regimen and the first one conducted among all Asian populations.

"The envelope protein of the HIV virus can fuse with human's cell membrane and inject its genetic material into the cell," said Yao Cheng, senior medical director with Frontier Biotech. "But ABT can bond with the envelop protein before its fusion with human cells, thereby blocking the infections."

The ABT can also bond with albumin, a human protein found in plasma, to extend its stay in the body, thus having long-lasting antiviral efficacy when administrated weekly, said Yao.

Plus, no drug-resistant mutation was found in the HIV virus after the 48-week medications, according to the trial.

The Chinese company is now exploring other ABT combination regimens to provide more alternative options for infectious disease treatment.

The global anti-HIV drug market grew from 22.9 billion U.S. dollars in 2013 to 34 billion U.S. dollars in 2018 and is expected to further expand to 46.7 billion U.S. dollars by 2023.

Related news

Most popular in 24h

MoreTop news

MoreVideo

LINE
Back to top About Us | Jobs | Contact Us | 齐发国际ag开户
Copyright ©1999-2022 Chinanews.com. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[申博官方代理] [京ICP备05004340号-1]
齐发国际ag开户
正规9亿娱乐开户 威尼斯人澳门注册 尊亿娱乐怎么注册 BG游戏网站大全 马可波罗赌博开户
金冠体育而生的专业平台 恒峰娱乐会员管理网 云顶彩票天津时时彩 银河线路检测中心 奔驰娱乐游戏最高占成
大富豪娱乐平台登录 彩77江苏快三 竟彩下注后会变化么 荣一网彩金 全新升级版U宝娱乐城
杏耀首存红利多少 玛雅娱乐开户送88元 申博怎么充值登入 菲律宾太阳网上娱乐登入 申博直营现金网